10-K: Modular Medical Secures FDA Clearance for Pivot Insulin Pump

Modular Medical, Inc. announced FDA clearance for its Pivot insulin delivery system, marking a significant step towards commercialization and broader market adoption.

Summary

• Modular Medical, Inc. has received FDA clearance for its Pivot insulin pump, a next-generation tubeless patch pump designed for ease of use and affordability.
• The company aims to expand the insulin pump market beyond 'super users' to the mass market, targeting both Type 1 and Type 2 diabetes patients.
• Commercial availability and initial shipments of the Pivot pump commenced in June 2026, with plans for expansion into metropolitan markets by late 2026.
• The company also plans to obtain CE mark clearance for the Pivot product by the second quarter of 2027 to enter European markets.
• Modular Medical reported net losses of $28.2 million for the year ended March 31, 2026, and $18.8 million for the year ended March 31, 2025, highlighting the need for continued capital raising.
• The company has a history of operating losses and expects to continue incurring losses as it scales operations and commercialization efforts.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant operating losses, accumulated deficit, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern, despite the positive news of FDA clearance for its product.

Positives

• Received FDA clearance for the Pivot insulin pump, enabling commercialization in the United States.
• Commenced initial shipments of the Pivot insulin delivery system in June 2026.
• Plans to expand commercial activities to metropolitan markets by late 2026.
• Intends to obtain CE mark clearance for the Pivot product by Q2 2027 for European market entry.
• The Pivot pump is designed with a focus on low cost, ease of use, and learnability, addressing key barriers to adoption.
• The company has established a manufacturing partnership with Phillips Medisize to scale production.
• Secured $3.0 million in net proceeds from a public offering in April 2026 to fund operations.

Negatives

• The company has a history of significant operating losses and expects to continue incurring losses.
• As of March 31, 2026, the company had cash and cash equivalents of $6.9 million and an accumulated deficit of $113.0 million.
• There is substantial doubt about the company's ability to continue as a going concern without additional capital.
• The company's ability to continue operations depends on raising additional capital, which may not be available on favorable terms or at all.
• Future capital raises are likely to result in significant dilution to existing stockholders.
• The company has not yet achieved profitability and may never do so.

Risks

• The company may not be able to continue as a going concern due to its history of operating losses and need for substantial additional funding.
• Failure to attract and retain skilled personnel, including key management, could impair product development and commercialization.
• Reliance on third-party manufacturers and suppliers makes the company vulnerable to supply shortages and quality issues.
• The company may not be able to successfully scale up manufacturing to meet demand.
• Competitors may develop more effective, safer, or less expensive products.
• Obtaining marketing authorization in other jurisdictions outside the U.S. will incur additional costs and may face delays.
• The company's intellectual property may not adequately protect its technology or provide a competitive advantage.
• The company is subject to extensive FDA regulation, which could restrict sales and marketing or lead to significant costs.
• Failure to obtain adequate reimbursement or insurance coverage for the Pivot pump could prevent significant revenue generation.
• The company's common stock could be delisted from Nasdaq if it fails to meet continued listing requirements.

Future Outlook

The company plans to expand commercial activities for its Pivot product across metropolitan markets in the U.S. by late 2026 and obtain CE mark clearance for European market entry by the second quarter of 2027. Future product development includes adding phone-based control and Automated Insulin Delivery (AID) capabilities.

Management Comments

• We believe that by simplifying and streamlining the user experience... we seek to expand the wearable insulin delivery device market beyond the highly motivated super users to expand the category into the mass market.
• Our goal is to become the leader in expanding access to insulin pump technology to a wider portion of people with diabetes by delivering an affordable, easy-to-use solution not just for the highly motivated super users, but diabetes care for the rest of us.
• We believe that the combination of our patch pump form factor, lower cost at scale and lower training burden is well suited for European markets where there are very few physicians or nurses available to provide training.

Industry Context

StockSavvy.ai notes that Modular Medical is entering a competitive diabetes device market, aiming to differentiate through a more accessible and user-friendly insulin pump. The company's strategy aligns with the broader trend of increasing adoption of wearable technology for chronic disease management, similar to the evolution seen in continuous glucose monitoring (CGM) devices.

Comparison to Industry Standards

• The company's Pivot pump aims to offer a cost of goods approximately 50% lower than its closest patch pump competitor at scale.
• The Pivot pump holds a 3 mL insulin reservoir, which is 50% more than Insulet's Omnipod (2 mL), addressing a key need for Type 2 diabetes patients who often require more insulin.
• The Pivot pump weighs 20 grams empty (vs. 26 grams for Omnipod) and 23 grams fully filled (vs. 28 grams for Omnipod), representing a 23% and 18% reduction in weight, respectively.
• The company's setup and refill process requires nine steps every 72 hours, compared to an estimated 42 steps for current commonly used insulin pumps.

Legal Proceedings

• The company is not a party to any material legal proceedings that are likely to have a material adverse effect on its consolidated financial position or results of operations.

Related Party Transactions

• Manchester Management Company, LLC (MMC), as general partner of Manchester Explorer, L.P. (Explorer), and its affiliates, including James Besser (CEO) and Morgan Frank (Director), purchased units in a private placement in March 2025.
• James Besser (CEO) purchased units in the March 2025 private placement.
• Two members of the Board purchased units in the March 2025 private placement.
• Two members of the Board participated in a December 2025 placement offering.
• The company issued a promissory note to James Besser in February 2026 for a $350,000 revolving credit facility, which was repaid in March 2026.
• A daughter of Paul DiPerna (President, CFO, Treasurer, Chairman) was an employee until March 15, 2026.
• A second daughter of Paul DiPerna consulted and became an employee during 2025.
• The company has a royalty agreement with its founder, Paul DiPerna, for intellectual property transfer.

Stakeholder Impact

• Existing stockholders may experience significant dilution due to future capital raises.
• The company's ability to continue as a going concern raises concerns for investors.
• Employees may be impacted by the company's financial performance and need for cost-cutting measures.
• Suppliers and partners may be affected by the company's financial stability and ability to meet obligations.

Next Steps

• Expand commercial activities for the Pivot product across metropolitan markets in the United States by late 2026.
• Obtain Conformite Europeenne (CE) mark clearance for the Pivot product by the second quarter of 2027.
• Continue to improve the manufacturability and usability of the Pivot product.
• Develop new pump products, including those with phone-based control and AID capabilities.
• Seek additional capital through equity or debt offerings to fund future operations and development.

Key Dates

Recommendation

While the FDA clearance for the Pivot insulin pump is a positive development, the company's significant operating losses, substantial accumulated deficit, and the explicit statement of doubt regarding its ability to continue as a going concern present considerable risk. The need for further capital raises, which will likely dilute existing shareholders, also weighs heavily. Investors should monitor the commercial launch and adoption of the Pivot pump, as well as the company's ability to secure necessary funding, before considering a more aggressive stance.

Keywords

Modular Medical, MODD, Pivot insulin pump, FDA clearance, diabetes, insulin delivery, medical device, Type 1 diabetes, Type 2 diabetes, patch pump, wearable technology, healthcare, SEC filing, 10-K